KURA peer analysis
Kura Oncology (KURA) against its competitors: price, today's move, 1-year return and market value side by side.
KURA and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BBOT BridgeBio Oncology | $2.31 | -11.83% | -80.65% | – |
| CRDF Cardiff Oncology | $0.84 | -5.09% | -64.07% | $69.21M |
| HCM HUTCHMED | $13.27 | 0.91% | -8.04% | $2.29B |
| NRIX Nurix Therapeutics | $25.70 | -4.10% | 98.61% | – |
| ORIC Oric | $9.07 | -1.84% | -31.08% | $957.75M |
| RIGL Rigel Pharmaceuticals | $50.53 | -1.52% | 60.01% | $958.46M |
| SLS SELLAS Life Sciences | $8.57 | 0.23% | 370.88% | $1.95B |
| SNDX Syndax Pharmaceuticals | $13.25 | 1.15% | -3.28% | $1.22B |
| TYRA Tyra Biosciences | $21.33 | 1.23% | 34.66% | – |
| VSTM Verastem | $9.59 | -1.64% | 1.48% | $1.18B |
| KURA Kura Oncology | $9.79 | -4.58% | -4.67% | $912.74M |
- KURA's peers: BBOT (BridgeBio Oncology), CRDF (Cardiff Oncology), HCM (HUTCHMED), NRIX (Nurix Therapeutics), ORIC (Oric), RIGL (Rigel Pharmaceuticals), SLS (SELLAS Life Sciences), SNDX (Syndax Pharmaceuticals).
Updated 2026-11-03 11:33 UTC